Pfizer (NYSE:PFE) Stock Price Down 1.6% – Should You Sell?

Pfizer Inc. (NYSE:PFE)’s share price dropped 1.6% on Friday . The stock traded as low as $26.80 and last traded at $26.9790. Approximately 63,437,137 shares traded hands during mid-day trading, an increase of 35% from the average daily volume of 46,982,953 shares. The stock had previously closed at $27.41.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase 3 TALAPRO-3 topline: TALZENNA (talazoparib) + XTANDI significantly improved radiographic progression‑free survival in HRR‑mutated metastatic castration‑sensitive prostate cancer — a late‑stage win that meaningfully expands Pfizer’s oncology indications and long‑term revenue optionality. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Atirmociclib phase II success in second‑line metastatic breast cancer supports pipeline diversification in oncology and could drive future partnering or late‑stage investment decisions. PFE’s Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst momentum: recent upgrades and positive forecasts (including HSBC coverage and other analyst notes) raise the probability of further buy‑side interest into the pipeline progress. HSBC Forecasts Strong Price Appreciation for Pfizer (NYSE:PFE) Stock
• Neutral Sentiment: Pfizer-linked Biotech Development Fund appeared in a large $787M financing for AI biologics startup Earendil Labs — signals continued strategic venture activity but limited near‑term earnings impact. Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
• Neutral Sentiment: Valuation/market commentary: pieces reassessing PFE’s valuation and comparing Pfizer vs. peers like Moderna reflect heightened investor focus on growth vs. income tradeoffs; useful for positioning but not immediate catalysts. Reassessing Pfizer (PFE) Valuation As Shares Trade Around Recent Levels
• Negative Sentiment: Policy/pricing scrutiny: coverage of TrumpRx pricing comparisons underscores continuing political and public scrutiny on drug pricing, a background risk that can weigh on sentiment for large pharma. Analysis-TrumpRx lists many medicines at prices higher than paid in UK

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on PFE shares. Barclays assumed coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price target for the company. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research report on Thursday, February 12th. Bank of America lowered their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Finally, Citigroup started coverage on Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.14.

Pfizer Trading Down 1.6%

The business’s 50-day simple moving average is $26.65 and its 200-day simple moving average is $25.59. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a market cap of $153.41 billion, a PE ratio of 19.84 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.63 earnings per share. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Institutional Investors Weigh In On Pfizer

Several institutional investors have recently made changes to their positions in PFE. Brighton Jones LLC grew its holdings in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the last quarter. United Bank boosted its holdings in shares of Pfizer by 12.4% during the 2nd quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after buying an additional 6,415 shares during the period. Stonebrook Private Inc. bought a new stake in shares of Pfizer during the 2nd quarter worth $234,000. Finally, Miller Financial Services LLC grew its stake in Pfizer by 4.8% in the 2nd quarter. Miller Financial Services LLC now owns 18,193 shares of the biopharmaceutical company’s stock valued at $441,000 after buying an additional 830 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.